Ovarian cancer has an annual incidence of 11.4 per 100,000 women in the United States, with a 5-year overall survival of 47.6% for all stages.1 In patients with fallopian tube or primary peritoneal ovarian cancer, a platinum-based (ie, carboplatin, cisplatin) regimen is the chemotherapy of choice in the metastatic or the adjuvant setting.²

Patients undergoing hematopoietic stem-cell transplantation (HSCT) often receive highly emetogenic, multiday conditioning chemotherapy. Many patients experience nausea and vomiting, which may negatively affect quality of life, despite receiving triple therapy with dexamethasone, a neurokinin-1 (NK-1) receptor antagonist, and serotonin receptor antagonists (5-HT₃).

The combination of atezolizumab immunotherapy plus bevacizumab improves survival as well as significantly delaying deterioration in quality of life compared with the current standard of the targeted therapy sorafenib in the treatment of patients with unresectable hepatocellular carcinoma (HCC).